4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Biotechnology

Healthcare
$10.79 +1.70%

+$0.16 today

Market cap
$596.08M
Beta
2.76
P/E (TTM)
-4.0
EPS (TTM)
-$2.36
52W Low $3.68High $12.34

Volume 0.81M

Average 0.77M

FDMT Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

4D Molecular Therapeutics, Inc.NASDAQ: FDMT

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to -2256.6%

Net margin was -2256.6% in Q1 FY2026, up 340400.5 pp from a year earlier. On a trailing-twelve-month basis it was -182.3%, up 766943.8 pp year over year. Over 3 fiscal years it widened by 3271.0 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 5 analysts of -1700.2% for the fiscal year ending Dec 2026, down from -164.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-2256.6%-2279.4 pp QoQ
Last fiscal yearDec 2025
-164.4%+434613.9 pp YoY
LTMMar 2026
-182.3%+766943.8 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+340400.5 pp+362357.5 pp+21957.0 pp
1 year+434613.9 pp-1535.8 pp-436149.7 pp
3 years+3271.0 pp-339.0 pp-3610.0 pp
5 years+146.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-164.4%
Year-over-year change
+434613.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How FDMT compares with its peers on the latest reported figures

  • FDMT's LTM Mar 2026 net margin of -182.3% is the 3rd highest of the 6 companies compared; the peer median is -330.2%.
  • Its year-over-year change of +766943.8 pp is the highest of 5, against a peer median of -153.5 pp.
  • Over three fiscal years its change of +3271.0 pp compares with a peer median of +673.9 pp.
FDMT Competitors Peer median
Net Margin for FDMT and competitors
Company Period LTM level YoY 3-year change
ABEOAbeona Therapeutics Inc.LTM Mar 2026454.9% —+4030.4 pp
MGTXMeiraGTx Holdings plcLTM Mar 2026-151.1% +333.8 pp+673.9 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-182.3% +766943.8 pp+3271.0 pp
RGNXREGENXBIO Inc.LTM Mar 2026-330.2% -229.6 pp+134.9 pp
QUREuniQure N.V.LTM Mar 2026-1154.4% -77.4 pp-1116.9 pp
OCGNOcugen, Inc.LTM Mar 2026-1605.2% -334.1 pp+1951.5 pp
SLDBSolid Biosciences Inc.FY2025— ——
LXEOLexeo Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding FDMT) -330.2%-153.5 pp+673.9 pp

Competitors are the stored peer set for FDMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue18.04M3.13M20.72M37K85.21M
Cost of Revenue61.36M80.25M97.1M141.3M7.63M
Gross Profit(43.32M)(77.12M)(76.37M)(141.26M)77.58M
Gross Margin-240.2%-2464.8%-368.5%-381789.2%91.1%
Research & Development61.36M80.25M97.1M141.3M195.7M
Selling, General & Admin28.01M32.91M36.49M46.58M49.06M
Operating Expenses28.01M32.91M36.49M46.58M237.13M
Depreciation & Amortization1.52M2.4M4.2M6.71M7.63M
EBITDA(69.79M)(105.09M)(96.63M)(154.16M)(132.48M)
EBITDA Margin-386.9%-3358.6%-466.3%-416656.8%-155.5%
Operating Income(71.33M)(110.03M)(112.87M)(187.84M)(159.55M)
Operating Margin-395.5%-3516.5%-544.6%-507678.4%-187.2%
Interest Income137K2.57M12.21M27.05M19.48M
Interest Expense00000
Other Income / Expenses16K2.54M12.03M26.97M19.44M
Income Before Tax(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Pre-Tax Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
Income Tax Expense00000
Net Income(71.32M)(107.49M)(100.84M)(160.87M)(140.11M)
Net Margin-395.4%-3435.4%-486.6%-434778.4%-164.4%
EPS (Basic)(2.46)(3.12)(2.58)(2.98)(2.42)
EPS (Diluted)(2.46)(3.12)(2.58)(2.98)(2.42)
Weighted Avg Shares27.73M32.35M39.13M53.94M57.93M
Weighted Avg Shares (Diluted)27.73M32.35M39.13M53.94M57.93M

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

Intrinsic Alpha fair value

Locked

Current Price

$10.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.